BAYR.Y Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €7.26 |
52 Week High | €16.81 |
52 Week Low | €6.96 |
Beta | 0.97 |
1 Month Change | -0.41% |
3 Month Change | -18.24% |
1 Year Change | -55.97% |
3 Year Change | -55.38% |
5 Year Change | -56.58% |
Change since IPO | 64.53% |
Recent News & Updates
Recent updates
Shareholder Returns
BAYR.Y | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.9% | 0.08% | 1.2% |
1Y | -56.0% | 13.2% | 24.9% |
Price Volatility
BAYR.Y volatility | |
---|---|
BAYR.Y Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BAYR.Y's share price has been volatile over the past 3 months.
Volatility Over Time: BAYR.Y's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYR.Y fundamental statistics | |
---|---|
Market cap | US$28.36b |
Earnings (TTM) | -US$3.15b |
Revenue (TTM) | US$50.98b |
0.6x
P/S Ratio-9.0x
P/E RatioIs BAYR.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYR.Y income statement (TTM) | |
---|---|
Revenue | €47.64b |
Cost of Revenue | €19.75b |
Gross Profit | €27.89b |
Other Expenses | €30.83b |
Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -2.99 |
Gross Margin | 58.55% |
Net Profit Margin | -6.17% |
Debt/Equity Ratio | 132.3% |
How did BAYR.Y perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-4%
Payout RatioDoes BAYR.Y pay a reliable dividends?
See BAYR.Y dividend history and benchmarksBayer dividend dates | |
---|---|
Ex Dividend Date | Apr 29 2024 |
Dividend Pay Date | May 13 2024 |
Days until Ex dividend | 4 days |
Days until Dividend pay date | 18 days |
Does BAYR.Y pay a reliable dividends?
See BAYR.Y dividend history and benchmarks